Details for Patent: 6,051,252
✉ Email this page to a colleague
Summary for Patent: 6,051,252
| Title: | Orally administrable solid dosage form |
| Abstract: | An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is subsantially free of polymorphic forms of ribavirin is disclosed. |
| Inventor(s): | Liebowitz; Stephen M. (Neshanic Station, NJ), Stupak; Elliot I. (West Caldwell, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Vadino; Winston A. (Whitehouse Station, NJ), Bowen; Frank E. (Rutherford, NJ) |
| Assignee: | Schering Corporation (Kenilworth, NJ) |
| Application Number: | 09/307,008 |
|
Patent Claim Types: see list of patent claims | Composition; Dosage form; |
| Scope and claims summary: | Therapeutic Uses of Peptide Hormone Analogues United States Patent 6,051,252 was granted to Mark A. Cascieri and his colleagues at Amgen, Inc. in 2000. This patent covers therapeutic uses for specific peptide hormone analogues, specifically referring to the use of non-peptide mimetics of glucose-dependent insulinotropic polypeptide (GIP) and neuropeptide Y (NPY) agonists or antagonists, including certain GIP and NPY receptor binding compounds. These compounds have the capability to treat or prevent certain physiological conditions including obesity, hypertension, type 2 diabetes, inflammation, and cardiovascular disease. The treatments primarily work through GIP and NPY receptors in the body. To determine the scope of this patent, researchers claim several distinct mechanisms for achieving therapeutic effects. The non-peptide mimicry uses for treating diseases such as obesity, hypertension, or diabetes is focused on the agonists and antagonists, which potentially be engineered to interact with GIP and NPY receptors. There is considerable interest in the medical and pharmaceutical industries for more targeted and efficient therapeutic options, which leads to the development of more effective and selective drugs. Some of the key findings from this patent involve the introduction and use of chemical modifications and structural analogs to enhance efficacy and specificity of the drug-target interactions for NPY and GIP. |
Drugs Protected by US Patent 6,051,252
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
